Photodynamic Therapy for Exudative Hamartoma in Tuberous Sclerosis

Mennel, Stefan; Hausmann, N.; Meyer, Carsten H.; Peter, Silvia

doi:10.1001/archopht.124.4.597

Cited by 34 publications

(23 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Barbazetto et al, 24 Campbell et al, 42 CanalFontcuberta et al, 43 Donaldson et al, 57 Mashayekhi et al, 118 Rundle et al, 153 Soucek et al, 185 Eskelin et al, 62 Mashayekhi et al, 118 Mennel et al, 120 …”

Section: Circumscribed Choroidal Hemangiomamentioning

confidence: 99%

Clinical use of photodynamic therapy in ocular tumors

Çerman

Çekıç

2015

Survey of Ophthalmology

View full text Add to dashboard Cite

Section: Circumscribed Choroidal Hemangiomamentioning

confidence: 99%

Clinical use of photodynamic therapy in ocular tumors

Çerman

Çekıç

2015

Survey of Ophthalmology

View full text Add to dashboard Cite

“…As the patient’s visual acuity (VA) continually decreased, we decided to perform ocular PDT to prevent permanent macular damage due to persistent macular edema and lipid accumulation. A single PDT treatment was performed [1]. The laser treatment spot was directed to the tumor vascularization.…”

Section: Photodynamic Therapy Of Ocular Tumorsmentioning

confidence: 99%

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 2)

et al. 2007

Self Cite

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has become a well-established treatment for vascular forms of age-related macular degeneration (AMD). The implementation of evidence-based medicine principles into the treatment regimen of AMD seems to be immensly important, since AMD continues to be the most frequent cause of blindness among patients older than 65 years in industrialized countries. Numerous randomized prospective studies demonstrated high levels of evidence for the efficacy of various treatment approaches such as laser photocoagulation, PDT, subretinal surgery or novel anti-angiogenic drugs [Arch Ophthalmol 2006;124:597–599]. The high evidence shown by these studies supported the rationale to use PDT also in additional, less frequent, vasoproliferative diseases. Although these ‘case series’ and ‘individual case control studies’ have a low level of evidence, they give us important information for treatment decisions in these rare conditions. The goal of this survey is to review the current literature regarding PDT in vasoproliferative and exudative ocular diseases outside AMD. Many studies modified the treatment parameters of PDT to address the specific pathology of the underlying disease. Table 1 summarizes the diseases and treatment parameters that are described in this part 2, the entire table of this review is included in part 1 (www.karger.com/doi/10.1159/ 000101922).

show abstract

“…83 s [1,37]. In a second approach, a double exposure time of 166 s was chosen, as used in PDT of choroidal [13] or papillary capillary hemangiomas [33] and in retinal tumors [19]. The laser treatment spot, 3500 μm in diameter, was applied without a magnifying lens and directed to the center of the RPE monolayer.…”

Section: Pdt Effect On the Rpe Barrier Functionmentioning

confidence: 99%